De-identified residual collection and testing with GenMarks Blood culture identification gram positive gram negative and fungal pathogen panels on the ePlex platform Arm 2 (CTP0010)
Evaluating the Accuracy of Diagnostic Assays on the ePlex Platform
Brief description of study.
The purpose of this study is to evaluate the sensitivity and specificity of the BCID-GN, BCID-GP and BCID-F assays on the ePlex platform.
Detailed description of study
The purpose of this study is to evaluate the sensitivity and specificity of the BCID-GN, BCID-GP and BCID-F assays on the ePlex platform.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Healthy
-
Age: 100 years or below
-
Gender: All
This study investigates the accuracy of certain diagnostic tests called assays on a machine known as the ePlex platform. The tests are referred to as BCID-GN, BCID-GP, and BCID-F assays, which help in identifying bacterial infections. Sensitivity and specificity are terms used to describe how well these tests can detect an infection and how accurately they can confirm the absence of an infection, respectively.
Participants in this study will undergo testing using the BCID-GN, BCID-GP, and BCID-F assays on the ePlex platform. These procedures are non-invasive and involve analyzing samples to determine the presence of bacterial infections. The results will help in understanding the effectiveness of these assays in diagnosing infections.
- Who can participate: Eligible participants are adults who are suspected of having bacterial infections.
- Study details: Participants will provide samples for testing with the BCID-GN, BCID-GP, and BCID-F assays on the ePlex platform. These tests are non-invasive and aim to diagnose bacterial infections accurately. No placebo is involved in this study.
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
Please choose between Voice or SMS based delivery of verification code
or